Objective: To investigate the frequencies and biological characteristics of CD25 positive hematopoietic stem cells (HSC) in myelodysplastic syndromes.
Methods: The expression of CD25 on HSC in bone marrow derived from patients with untreated MDS patients, untreated AML patients and normal controls were accessed by flow cytometry (FCM). The correlation analysis was done between CD25 HSC and clinical parameters in MDS patients.
Results: The expression of CD25 on HSC (CD34CD38 cells) in MDS patients (28.81%) was significantly higher than that in normal controls (9.41%, P = 0.020), which similar to that in AML patients (32.54%, P = 0.410). The CD25 expression on HSC was positively correlated with the CD123 expression on HSC (r = 0.602, P = 0.008). The expression of CD25 on HSC in high-risk MDS group (53.27%) based on IPSS score was significantly higher than that in low-risk MDS group (18.66%, P = 0.003). In MDS patients, CD25 HSC were negatively correlated with the counts of neutrophils (r = -0.684, P = 0.002) and platelets (r = -0.561, P = 0.015), while positively correlated with the percentage of blasts in bone marrow (r = 0.596, P = 0.009). The CD25 expression on erythroblasts had a significant positive correlation with red blood cell counts in MDS patients (r = 0.536, P = 0.012).
Conclusions: CD25 was over-expressed on HSC in MDS patients, especially in high-risk MDS patients. Increased CD25 HSC was correlated with progression of MDS. Low-expression of CD25 on erythroblasts might correlate with anemia in MDS patients. CD25 could be a specific marker of LSC in MDS, and could involve in the mechanisms of development and progression of MDS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.leukres.2017.11.010 | DOI Listing |
Eur J Neurol
January 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Background: Catechol-O-methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa-treated patients without motor complications.
Methods: This was a randomized, double-blind, 24-week, placebo-controlled study of opicapone 50 mg as adjunct to levodopa (NCT04978597).
Disaster Med Public Health Prep
January 2025
Department of Global Public Health Karolinska Institutet, Sweden.
On February 6, 2023, a strong earthquake (7.8 Richter scale) shook southwestern Türkiye, and also affected areas in northwest Syria, resulting in over 50 000 fatalities and more than 100 000 injured in Türkiye, in addition to the displacement of approximately 3 million people. In response to an international request for assistance from the Turkish government, the United Kingdom (UK) government deployed an Emergency Medical Team (EMT) Type 1 to provide outpatient care.
View Article and Find Full Text PDFBMC Geriatr
January 2025
Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objectives: Freezing of Gait (FOG) is one of the disabling symptoms in patients with Parkinson's Disease (PD). While it is difficult to early detect because of the sporadic occurrence of initial freezing events. Whether the characteristic of gait impairments in PD patients with FOG during the 'interictal' period is different from that in non-FOG patients is still unclear.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address:
Ethnopharmacological Relevance: Myelodysplastic syndrome (MDS) is a hematologic malignancy that presents a unique opportunity for traditional Chinese medicine (TCM) to demonstrate its distinctive value in treatment. Realgar, a component of TCM, has shown notable potential in alleviating clinical symptoms and improving the prognosis of MDS patients. However, the precise mechanisms underlying the treatment of MDS with realgar, particularly its effects on apoptosis-related pathways, remain poorly understood.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pulmonary surfactant (PS) is one of the main treatment for neonates with respiratory distress syndrome (RDS). Budesonide has recently been studied as an additional treatment in such cases, but there is limited evidence supporting this. This study was implemented to determine the efficacy of PS combined with budesonide in premature infants.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!